64
Participants
Start Date
January 31, 2013
Primary Completion Date
December 31, 2016
Study Completion Date
August 31, 2017
Drug (Direct thrombin or Factor Xa inhibitor)
Patient will stop or restart drug per cardiac device information (AT/AF diagnostics for prespecified AT/AF episode duration per day and total burden).
Allegheny Singer Research Institute, Pittsburgh
Jefferson Heart Institute, Philadelphia
Sparrow Research Institute, Lansing
Northwestern Memorial Hospital, Chicago
Hackensack University Medical Center, Hackensack
STAR Clinical Trials, LLC / Cardiology Clinic of San Antonio, San Antonio
Jeffrey Goodman, MD, Los Angeles
Samaritan Heart and Vascular Institute, Corvallis
Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Lead Sponsor
Abbott Medical Devices
INDUSTRY